Psoriasis Biosimilars Market Size, Share, and Trends 2024 to 2034

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID -19 Impact on Psoriasis Biosimilars Market 

5.1. COVID-19 Landscape: Psoriasis Biosimilars Industry Impact

5.2. COVID -19  Impact Assessment for the Industry

5.3. COVID - 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Psoriasis Biosimilars Market, By Drug Class

8.1. Psoriasis Biosimilars Market Revenue and Volume Forecast, by Drug Class, 2024-2034

8.1.1. TNF-Alpha Inhibitors

8.1.1.1. Market Revenue and Volume Forecast (2021-2034)

8.1.2. Infliximab

8.1.2.1. Market Revenue and Volume Forecast (2021-2034)

8.1.3. Etanercept

8.1.3.1. Market Revenue and Volume Forecast (2021-2034)

8.1.4. Adalimumab

8.1.4.1. Market Revenue and Volume Forecast (2021-2034)

8.1.5. Other Biosimilars

8.1.5.1. Market Revenue and Volume Forecast (2021-2034)

Chapter 9. Global Psoriasis Biosimilars Market, By Indication

9.1. Psoriasis Biosimilars Market Revenue and Volume Forecast, by Indication, 2024-2034

9.1.1. Plaque Psoriasis

9.1.1.1. Market Revenue and Volume Forecast (2021-2034)

9.1.2. Psoriatic Arthritis

9.1.2.1. Market Revenue and Volume Forecast (2021-2034)

9.1.3. Other Types

9.1.3.1. Market Revenue and Volume Forecast (2021-2034)

Chapter 10. Global Psoriasis Biosimilars Market, By Route of Administration

10.1. Psoriasis Biosimilars Market Revenue and Volume Forecast, by Route of Administration, 2024-2034

10.1.1. Subcutaneous

10.1.1.1. Market Revenue and Volume Forecast (2021-2034)

10.1.2. Intravenous

10.1.2.1. Market Revenue and Volume Forecast (2021-2034)

10.1.3. Oral

10.1.3.1. Market Revenue and Volume Forecast (2021-2034)

10.1.4. Topical

10.1.4.1. Market Revenue and Volume Forecast (2021-2034)

Chapter 11. Global Psoriasis Biosimilars Market, By Sales Channel 

11.1. Psoriasis Biosimilars Market Revenue and Volume Forecast, by Sales Channel, 2024-2034

11.1.1. Hospital Pharmacies

11.1.1.1. Market Revenue and Volume Forecast (2021-2034)

11.1.2. Retail Pharmacy Chains

11.1.2.1. Market Revenue and Volume Forecast (2021-2034)

11.1.3. Online Pharmacies

11.1.3.1. Market Revenue and Volume Forecast (2021-2034)

Chapter 12. Global Psoriasis Biosimilars Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Volume Forecast, by Drug Class (2021-2034)

12.1.2. Market Revenue and Volume Forecast, by Indication (2021-2034)

12.1.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2034)

12.1.4. Market Revenue and Volume Forecast, by Sales Channel (2021-2034)

12.1.5. U.S.

12.1.5.1. Market Revenue and Volume Forecast, by Drug Class (2021-2034)

12.1.5.2. Market Revenue and Volume Forecast, by Indication (2021-2034)

12.1.5.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2034)

12.1.5.4. Market Revenue and Volume Forecast, by Sales Channel (2021-2034)

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Volume Forecast, by Drug Class (2021-2034)

12.1.6.2. Market Revenue and Volume Forecast, by Indication (2021-2034)

12.1.6.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2034)

12.1.6.4. Market Revenue and Volume Forecast, by Sales Channel (2021-2034)

12.2. Europe

12.2.1. Market Revenue and Volume Forecast, by Drug Class (2021-2034)

12.2.2. Market Revenue and Volume Forecast, by Indication (2021-2034)

12.2.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2034)

12.2.4. Market Revenue and Volume Forecast, by Sales Channel (2021-2034)

12.2.5. UK

12.2.5.1. Market Revenue and Volume Forecast, by Drug Class (2021-2034)

12.2.5.2. Market Revenue and Volume Forecast, by Indication (2021-2034)

12.2.5.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2034)

12.2.5.4. Market Revenue and Volume Forecast, by Sales Channel (2021-2034)

12.2.6. Germany

12.2.6.1. Market Revenue and Volume Forecast, by Drug Class (2021-2034)

12.2.6.2. Market Revenue and Volume Forecast, by Indication (2021-2034)

12.2.6.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2034)

12.2.6.4. Market Revenue and Volume Forecast, by Sales Channel (2021-2034)

12.2.7. France

12.2.7.1. Market Revenue and Volume Forecast, by Drug Class (2021-2034)

12.2.7.2. Market Revenue and Volume Forecast, by Indication (2021-2034)

12.2.7.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2034)

12.2.7.4. Market Revenue and Volume Forecast, by Sales Channel (2021-2034)

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Volume Forecast, by Drug Class (2021-2034)

12.2.8.2. Market Revenue and Volume Forecast, by Indication (2021-2034)

12.2.8.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2034)

12.2.8.4. Market Revenue and Volume Forecast, by Sales Channel (2021-2034)

12.3. APAC

12.3.1. Market Revenue and Volume Forecast, by Drug Class (2021-2034)

12.3.2. Market Revenue and Volume Forecast, by Indication (2021-2034)

12.3.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2034)

12.3.4. Market Revenue and Volume Forecast, by Sales Channel (2021-2034)

12.3.5. India

12.3.5.1. Market Revenue and Volume Forecast, by Drug Class (2021-2034)

12.3.5.2. Market Revenue and Volume Forecast, by Indication (2021-2034)

12.3.5.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2034)

12.3.5.4. Market Revenue and Volume Forecast, by Sales Channel (2021-2034)

12.3.6. China

12.3.6.1. Market Revenue and Volume Forecast, by Drug Class (2021-2034)

12.3.6.2. Market Revenue and Volume Forecast, by Indication (2021-2034)

12.3.6.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2034)

12.3.6.4. Market Revenue and Volume Forecast, by Sales Channel (2021-2034)

12.3.7. Japan

12.3.7.1. Market Revenue and Volume Forecast, by Drug Class (2021-2034)

12.3.7.2. Market Revenue and Volume Forecast, by Indication (2021-2034)

12.3.7.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2034)

12.3.7.4. Market Revenue and Volume Forecast, by Sales Channel (2021-2034)

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Volume Forecast, by Drug Class (2021-2034)

12.3.8.2. Market Revenue and Volume Forecast, by Indication (2021-2034)

12.3.8.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2034)

12.3.8.4. Market Revenue and Volume Forecast, by Sales Channel (2021-2034)

12.4. MEA

12.4.1. Market Revenue and Volume Forecast, by Drug Class (2021-2034)

12.4.2. Market Revenue and Volume Forecast, by Indication (2021-2034)

12.4.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2034)

12.4.4. Market Revenue and Volume Forecast, by Sales Channel (2021-2034)

12.4.5. GCC

12.4.5.1. Market Revenue and Volume Forecast, by Drug Class (2021-2034)

12.4.5.2. Market Revenue and Volume Forecast, by Indication (2021-2034)

12.4.5.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2034)

12.4.5.4. Market Revenue and Volume Forecast, by Sales Channel (2021-2034)

12.4.6. North Africa

12.4.6.1. Market Revenue and Volume Forecast, by Drug Class (2021-2034)

12.4.6.2. Market Revenue and Volume Forecast, by Indication (2021-2034)

12.4.6.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2034)

12.4.6.4. Market Revenue and Volume Forecast, by Sales Channel (2021-2034)

12.4.7. South Africa

12.4.7.1. Market Revenue and Volume Forecast, by Drug Class (2021-2034)

12.4.7.2. Market Revenue and Volume Forecast, by Indication (2021-2034)

12.4.7.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2034)

12.4.7.4. Market Revenue and Volume Forecast, by Sales Channel (2021-2034)

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Volume Forecast, by Drug Class (2021-2034)

12.4.8.2. Market Revenue and Volume Forecast, by Indication (2021-2034)

12.4.8.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2034)

12.4.8.4. Market Revenue and Volume Forecast, by Sales Channel (2021-2034)

12.5. Latin America

12.5.1. Market Revenue and Volume Forecast, by Drug Class (2021-2034)

12.5.2. Market Revenue and Volume Forecast, by Indication (2021-2034)

12.5.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2034)

12.5.4. Market Revenue and Volume Forecast, by Sales Channel (2021-2034)

12.5.5. Brazil

12.5.5.1. Market Revenue and Volume Forecast, by Drug Class (2021-2034)

12.5.5.2. Market Revenue and Volume Forecast, by Indication (2021-2034)

12.5.5.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2034)

12.5.5.4. Market Revenue and Volume Forecast, by Sales Channel (2021-2034)

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Volume Forecast, by Drug Class (2021-2034)

12.5.6.2. Market Revenue and Volume Forecast, by Indication (2021-2034)

12.5.6.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2034)

12.5.6.4. Market Revenue and Volume Forecast, by Sales Channel (2021-2034)

Chapter 13. Company Profiles

13.1. Merck KGaA

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. Gyros Protein Technologies AB

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. Pfizer Inc.

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. Novartis International AG

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. Amgen Inc

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. Abbott

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. Fresenius Kabi

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. Viatris

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. Reddy's Laboratories

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

13.10. GenScript

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial Performance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms